Showing results (191-200 of 364) with videos related to
Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemiaMary V Relling, Wenjian Yang, Soma Das, et al.Cancer|July 6, 2017
Longitudinal regret after treatment for low- and intermediate-risk prostate cancerLauren M Hurwitz, Jennifer Cullen, Daniel J Kim, et al.The Pharmacogenomics Journal|April 15, 2015
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication studyD J Crona, J Ramirez, W Qiao, et al.Cancer Chemotherapy and Pharmacology|August 5, 2008
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compoundsFederico Innocenti, Snezana Mirkov, Ramamoorthy Nagasubramanian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B studyR C Lilenbaum, M J Ratain, A A Miller, et al.Pathology|September 24, 2020
Prognostic features of Annexin A2 expression in prostate cancerShyh-Han Tan, Denise Young, Yongmei Chen, et al.The Oncologist|March 1, 2018
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung CancerKristen A Marrone, Xian Zhou, Patrick M Forde, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.Urologic Oncology|January 24, 2017
A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapyJohn S Banerji, Lauren M Hurwitz, Jennifer Cullen, et al.Pageof 37